ANP (Atrial Natriuretic Peptide)

ANP is a cardiac hormone released by atrial myocytes in response to stretch. It promotes natriuresis, diuresis, and vasodilation, playing key roles in blood pressure and fluid regulation.

Mechanism of Action

Binds to natriuretic peptide receptors (NPR-A) to activate guanylyl cyclase, producing cGMP. This leads to vasodilation, increased kidney filtration, and inhibition of the renin-angiotensin-aldosterone system.

Typical Dosage (Research)

Clinical use: Carperitide (recombinant ANP) used in Japan for acute heart failure at 0.1mcg/kg/min IV infusion.

Intravenous infusion only for clinical applications. Short half-life (~2 minutes) requires continuous administration.

Side Effects & Risks

Hypotension (dose-limiting), headache, nausea, and potential arrhythmias at high doses.

Significant hypotension risk. Requires careful monitoring. Not widely approved outside Japan.

Who Uses ANP (Atrial Natriuretic Peptide)

Heart failure patients (in Japan), cardiovascular researchers, those studying natriuretic peptide system.